NCT05655013View on ClinicalTrials.gov

Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis 2 (ZOLARMAB2)

PHASE4Active, not recruitingINTERVENTIONAL

Enrollment

200

Participants

Timeline

Start Date

May 10, 2023

Primary Completion Date

February 1, 2027

Study Completion Date

February 1, 2027

Conditions

Osteoporosis, Postmenopausal

Interventions

DRUG

Zoledronate

zoledronate 5 mg

DRUG

Placebo

isotonic saline 100 mL

Trial Locations (1)

Unknown

Aarhus University Hospital, Aarhus

All Listed Sponsors

lead

Aarhus University Hospital

OTHER